Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations
Open Access
- 12 August 2013
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (9), 1570-1576
- https://doi.org/10.2967/jnumed.112.113654
Abstract
Several methods are in use for analyzing 11C-Pittsburgh compound-B (11C-PiB) data. The objective of this study was to identify the method of choice for measuring longitudinal changes in specific 11C-PiB binding. Methods: Dynamic 90-min 11C-PiB baseline and follow-up scans (interval, 30 ± 5 mo) were obtained for 7 Alzheimer disease (AD) patients, 11 patients with mild cognitive impairment (MCI), and 11 healthy controls. Parametric images were generated using reference parametric mapping (RPM2), reference Logan values, and standardized uptake value volume ratios (SUVr), the latter for intervals between 60 and 90 (SUVr60–90) and 40 and 60 (SUVr40–60) minutes after injection. In all analyses, cerebellar gray matter was used as a reference region. A global cortical volume of interest was defined using a probability map–based template. Percentage change between baseline and follow-up was derived for all analytic methods. Results: SUVr60–90 and SUVr40–60 overestimated binding with 13% and 10%, respectively, compared with RPM2. Reference Logan values were on average 6% lower than RPM2. Both SUVr measures showed high intersubject variability. Over time, R1, the delivery of tracer to the cortex relative to that to the cerebellum, decreased in AD patients (P < 0.05) but not in MCI patients and controls. Simulations showed that SUVr, but not RPM2 and reference Logan values, was highly dependent on uptake period and that changes in SUVr over time were sensitive to changes in flow. Conclusion: To reliably assess amyloid binding over time—for example, in drug intervention studies—it is essential to use fully quantitative methods for data acquisition and analysis.Keywords
This publication has 27 references indexed in Scilit:
- Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal studyBrain, 2012
- Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyThe Lancet Neurology, 2010
- Follow-up of [ 11 C]PIB uptake and brain volume in patients with Alzheimer disease and controlsNeurology, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PETJournal of Nuclear Medicine, 2009
- Two-year follow-up of amyloid deposition in patients with Alzheimer's diseaseBrain, 2006
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Simplified Reference Tissue Model for PET Receptor StudiesNeuroImage, 1996
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991